https://pharmadevicenews.com/lineage-buys-a-huntingtons-disease-cell-therapy-with-six-patients-treated-can-hunt1-overcome-the-next-hurdle/ PharmaDeviceNews en 2026-11-13T03:58:39+00:00 Lineage buys a Huntington’s disease cell therapy with six patients treated. Can HUNT1 overcome the next hurdle? Brian Culley, California Institute for Regenerative Medicine, hNSC-01, HUNT1, Leslie Thompson, Lineage Cell Therapeutics, NeuroAirmid Therapeutics, REGEN4HD, University of California Irvine https://pharmadevicenews.com/wp-content/uploads/2026/07/Huntingtons-disease-drug-research-e1783863352980.webp https://pharmadevicenews.com/ardent-health-is-buying-a-480m-revenue-hospital-system-for-47m-whats-behind-the-deal/ PharmaDeviceNews en 2026-11-13T03:55:43+00:00 Ardent Health is buying a $480m revenue hospital system for $47m. What’s behind the deal? Ardent Health, Boone Health, Boone Health Medical Group, Boone Hospital Center, Columbia, Dave Caspers, Missouri https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/diamedica-has-reached-200-stroke-trial-patients-could-its-next-two-readouts-change-dm199s-future/ PharmaDeviceNews en 2026-11-13T03:52:08+00:00 DiaMedica has reached 200 stroke trial patients. Could its next two readouts change DM199’s future? DiaMedica Therapeutics, DM199, Health Canada, ReMEDy2, Tygerberg Hospital, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Clinical-Trials.webp https://pharmadevicenews.com/what-veradermics-latest-oral-minoxidil-data-reveal-about-long-term-hair-growth/ PharmaDeviceNews en 2026-11-13T03:48:39+00:00 What Veradermics’ latest oral minoxidil data reveal about long-term hair growth Jefferies, Study 302, Study 304, Study 306, United States Food and Drug Administration, VDPHL01, Veradermics https://pharmadevicenews.com/wp-content/uploads/2026/07/VDPHL01-female-hair-loss-data-to-test-Veradermics-extended-release-minoxidil-strategy-e1784095007570.webp https://pharmadevicenews.com/aptar-pharma-just-removed-a-critical-development-barrier-for-complex-nasal-drugs-how-much-could-change/ PharmaDeviceNews en 2026-11-13T03:45:29+00:00 Aptar Pharma gains DEA registration for controlled-substance nasal and inhaled drug development Aptar Pharma, AptarGroup, Boonton, New Jersey, United States Drug Enforcement Administration https://pharmadevicenews.com/wp-content/uploads/2026/05/Aptar-Pharma-advances-FDA-backed-research-into-next-generation-metered-dose-inhalers-e1778298889267.webp https://pharmadevicenews.com/pimjetmi-shrank-tumours-in-56-of-tgct-patients-can-merck-kgaa-break-through-an-increasingly-crowded-rare-tumour-market/ PharmaDeviceNews en 2026-11-12T07:09:51+00:00 Pimjetmi shrank tumours in 56% of TGCT patients. Can Merck KGaA break through an increasingly crowded rare-tumour market? Abbisko Medicine, EMD Serono, MANEUVER, Merck KGaA, pimicotinib, Pimjetmi, Romvimza, Turalio https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Cancer-generic.webp https://pharmadevicenews.com/risto-cel-stopped-severe-sickle-cell-crises-long-enough-for-beam-to-plan-a-bla-why-did-the-stock-still-fall/ PharmaDeviceNews en 2026-11-12T04:07:51+00:00 Risto-cel stopped severe sickle cell crises long enough for Beam to plan a BLA. Why did the stock still fall? BEACON, Beam Therapeutics, Casgevy, Genetix Biotherapeutics, LYFGENIA, risto-cel, ristoglogene autogetemcel, United States Food and Drug Administration, Vertex Pharmaceuticals https://pharmadevicenews.com/wp-content/uploads/2026/07/Vertex-wins-broader-CASGEVY-approval-as-pediatric-gene-therapy-enters-a-new-phase-e1782965191835.webp https://pharmadevicenews.com/abbott-just-put-physiologic-pacing-and-defibrillation-on-one-lead-can-ultisynq-change-how-icds-are-implanted/ PharmaDeviceNews en 2026-11-12T04:01:59+00:00 Abbott just put physiologic pacing and defibrillation on one lead. Can UltiSynq change how ICDs are implanted? Abbott Laboratories, ASCEND CSP, UltiSynq, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/two-phase-3-wins-put-comp360-before-the-fda-can-compass-pathways-turn-psilocybin-into-a-mainstream-depression-treatment/ PharmaDeviceNews en 2026-11-12T03:58:18+00:00 Two Phase 3 wins put COMP360 before the FDA. Can Compass Pathways turn psilocybin into a mainstream depression treatment? COMP005, COMP006, COMP360, COMPASS Pathways https://pharmadevicenews.com/wp-content/uploads/2026/05/Evecxia-Therapeutics-positions-EVX-101-as-adjunctive-therapy-for-OCD-and-depression-e1780030000546.webp https://pharmadevicenews.com/genedx-analysed-more-than-300000-patients-and-found-actionable-results-in-62-of-positive-cases-why-did-wgs-crash-17/ PharmaDeviceNews en 2026-11-12T03:53:20+00:00 GeneDx analysed more than 300,000 patients and found actionable results in 62% of positive cases. Why did WGS crash 17%? ExomeDx, GeneDx, GeneDx Infinity, GenomeDx, National Society of Genetic Counselors https://pharmadevicenews.com/wp-content/uploads/2026/05/Inocras-CancerVision-data-point-to-a-harder-question-for-ovarian-cancer-diagnostics-e1779511076970.webp